22236-1-AP

antibody from Proteintech Group

Targeting: BRD2 BRD2-IT1, D6S113E, FSRG1, KIAA9001, NAT, RING3

Provider product page for 22236-1-AP

Western blot

ELISA

Immunocytochemistry

Immunoprecipitation

Antibody data

Antibody Data
Antigen structure
References [15]
Comments [0]
Validations [0]

Submit

Product number: 22236-1-AP - Provider product page
Provider: Proteintech Group
Proper citation: Proteintech Cat#22236-1-AP, RRID:AB_2722524
Product name: BRD2 antibody
Antibody type: Polyclonal
Description: BRD2 antibody (Cat. #22236-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IP, WB,ELISA.
Reactivity: Human
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 20ul, 150ul

BRD2 protein structure - 22236-1-AP shown in red.

Submitted references BRD4-mediated transcriptional activation of PDLIM4 enhances p21 stability and chemosensitivity in lung adenocarcinoma independent of p53.

Wang Q, Guo L, Wang S, Guan C, Pan J, Zhu S, Zheng L, Wu X, Gu Y, Shu T, Luo L, Lai T, Gao X
BMC biology 2026 Jan 17;24(1):37

Design of PROTACs utilizing the E3 ligase GID4 for targeted protein degradation.

Li Y, Bao K, Sun J, Ge R, Zhang Q, Zhang B, Yan X, Li J, Shi F, Zhang M, Zang J, Liu M, Zhou J, Mi W, Xie S, Chen D, Shi L, Dong C
Nature structural & molecular biology 2025 Sep;32(9):1825-1837

INO80/SWR remodelers regulate Pol II transcription through BRD2 and chromatin landscape.

Liu M, Xu Q, Wang H, Ji X
Nucleic acids research 2025 Sep 5;53(17)

Histone demethylase KDM9 activates the CCND1/AKT pathway to promote the malignant progression of gliomas through interaction with BRD2.

Cheng J, Peng X, Tang S, Zhou P, Zhou Z, Mao Z, Li D, Yang L, Peng J
Cellular and molecular life sciences : CMLS 2025 Nov 26;82(1):423

BRD4 regulates m(6)A of ESPL1 mRNA via interaction with ALKBH5 to modulate breast cancer progression.

Zhang H, Lu L, Yi C, Jiang T, Lu Y, Yang X, Zhong K, Zhou J, Li J, Xie G, Chen Z, Jiang Z, Asadikaram G, Peng Y, Zhou D, Wang H
Acta pharmaceutica Sinica. B 2025 Mar;15(3):1552-1570

Apabetalone alleviates ligature-induced periodontitis by inhibiting M1 macrophage polarization via an immunometabolic shift.

Bian T, Li H, Liu H, Guo M, Zhang Y, Hu P, Chen M
International immunopharmacology 2025 Mar 26;150:114279

BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer.

Morino S, Mashima T, Shirai F, Nagayama S, Katayama R, Seimiya H
Cancer letters 2024 Mar 1;584:216632

Mitochondrial Control of Proteasomal Psmb5 Drives the Differentiation of Tissue-Resident Memory T Cells in Patients with Rheumatoid Arthritis.

Wu T, Su D, Zhang L, Liu T, Wang Q, Yan C, Liu M, Ji H, Lei J, Zheng M, Wen Z
Arthritis & rheumatology (Hoboken, N.J.) 2024 Dec;76(12):1743-1757

Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors.

Li J, Hu Q, Zhu R, Dong R, Shen H, Hu J, Zhang C, Zhang X, Xu T, Xiang Q, Zhang Y, Lin B, Zhao L, Wu X, Xu Y
Journal of medicinal chemistry 2024 Dec 12;67(23):21577-21616

A di-acetyl-decorated chromatin signature couples liquid condensation to suppress DNA end synapsis.

Bao K, Ma Y, Li Y, Shen X, Zhao J, Tian S, Zhang C, Liang C, Zhao Z, Yang Y, Zhang K, Yang N, Meng FL, Hao J, Yang J, Liu T, Yao Z, Ai D, Shi L
Molecular cell 2024 Apr 4;84(7):1206-1223.e15

The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage.

Zhu X, Liu W, Tang X, Chen Y, Ge X, Ke Q, Liang X, Gan Y, Zheng Y, Zou M, Deng M, Liu Y, Li DW, Gong L
Journal of neuroinflammation 2023 May 22;20(1):119

The H2A.Z and NuRD associated protein HMG20A controls early head and heart developmental transcription programs.

Herchenröther A, Gossen S, Friedrich T, Reim A, Daus N, Diegmüller F, Leers J, Sani HM, Gerstner S, Schwarz L, Stellmacher I, Szymkowiak LV, Nist A, Stiewe T, Borggrefe T, Mann M, Mackay JP, Bartkuhn M, Borchers A, Lan J, Hake SB
Nature communications 2023 Jan 28;14(1):472

Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.

Wang W, Tang YA, Xiao Q, Lee WC, Cheng B, Niu Z, Oguz G, Feng M, Lee PL, Li B, Yang ZH, Chen YF, Lan P, Wu XJ, Yu Q
Nature communications 2021 Jul 21;12(1):4441

The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer.

Bian X, Wang X, Zhang Q, Ma L, Cao G, Xu A, Han J, Huang J, Lin W
Frontiers in oncology 2020;10:565820

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.

Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei W
Nature medicine 2017 Sep;23(9):1063-1071

No comments: Submit comment

No validations: Submit validation data